HP
BIO icon

Hound Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Hound Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.6M Sell
22,481
-75,243
-77% -$21.3M 0.76% 20
2026
Q1 		$27.2M Buy
97,724
+54,456
+126% +$15.7M 3.41% 9
2025
Q4 		$13.1M Sell
43,268
-60,695
-58% -$18.9M 1.76% 14
2025
Q3 		$29.2M Sell
103,963
-77,973
-43% -$21.2M 3.74% 7
2025
Q2 		$43.9M Sell
181,936
-19,847
-10% -$4.69M 5.93% 7
2025
Q1 		$49.1M Buy
201,783
+142,925
+243% +$43M 9.75% 5
2024
Q4 		$19.3M Sell
58,858
-9,502
-14% -$3.23M 7.42% 4
2024
Q3 		$22.9M Sell
68,360
-96,510
-59% -$30.7M 5.72% 6
2024
Q2 		$45M Sell
164,870
-99,667
-38% -$29M 9.03% 4
2024
Q1 		$91.5M Buy
264,537
+2,873
+1% +$945K 27.27% 1
2023
Q4 		$84.5M Buy
261,664
+47,682
+22% +$14.9M 26.33% 1
2023
Q3 		$76.7M Sell
213,982
-2,564
-1% -$989K 17% 2
2023
Q2 		$82.1M Buy
216,546
+96,970
+81% +$39.5M 18.63% 1
2023
Q1 		$57.3M Buy
119,576
+31,222
+35% +$14.6M 14.42% 1
2022
Q4 		$37.2M Buy
88,354
+34,947
+65% +$14.1M 10.99% 5
2022
Q3 		$22.3M Sell
53,407
-10,014
-16% -$4.99M 4.23% 8
2022
Q2 		$31.4M Buy
+63,421
New +$33M 2.55% 12
2021
Q3 		– Sell
-72,264
Closed -$46.6M – 212
2021
Q2 		$46.6M Sell
72,264
-5,593
-7% -$3.4M 2.25% 17
2021
Q1 		$44.5M Buy
77,857
+4,285
+6% +$2.54M 2.1% 18
2020
Q4 		$42.9M Sell
73,572
-13,522
-16% -$7.7M 2.72% 17
2020
Q3 		$44.9M Sell
87,094
-558
-0.6% -$283K 3.04% 15
2020
Q2 		$39.6M Sell
87,652
-22,300
-20% -$9.84M 3.6% 13
2020
Q1 		$38.5M Buy
+109,952
New +$40.4M 3.6% 12

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ariel Investments
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Hound Partners's BIO Position: Q2 2026 in Review

Hound Partners reduced its Bio-Rad Laboratories Class A (BIO) stake by 77% in Q2 2026, selling an estimated $21.3M and leaving 22,481 shares worth $6.6M. The position accounts for 0.76% of the portfolio, ranked #20.

Hound Partners first reported a position in BIO in Q1 2020 and has held it in 23 quarters since. The position peaked at $91.5M in Q1 2024. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Hound Partners held 22,481 shares of Bio-Rad Laboratories Class A worth $6.6M as of Q2 2026.
  • Hound Partners sold 75,243 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $21.3M.
  • Bio-Rad Laboratories Class A made up 0.76% of Hound Partners's portfolio in Q2 2026, its #20 holding.
  • Hound Partners first reported a position in Bio-Rad Laboratories Class A in Q1 2020 and has held it in 23 quarters since.
  • Hound Partners's Bio-Rad Laboratories Class A position peaked at $91.5M in Q1 2024.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Hound Partners's 13F filing for Q2 2026, filed 14 Aug 2026.